SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells

Erin L. Wuebben, Phillip J. Wilder, Jesse L. Cox, James A. Grunkemeyer, Thomas Caffrey, Michael A Hollingsworth, A Angie Rizzino

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly deadly malignancy. Expression of the stem cell transcription factor SOX2 increases during progression of PDAC. Knockdown of SOX2 in PDAC cell lines decreases growth in vitro; whereas, stable overexpression of SOX2 in one PDAC cell line reportedly increases growth in vitro. Here, we reexamined the role of SOX2 in PDAC cells, because inducible SOX2 overexpression in other tumor cell types inhibits growth. In this study, four PDAC cell lines were engineered for inducible overexpression of SOX2 or inducible knockdown of SOX2. Remarkably, inducible overexpression of SOX2 in PDAC cells inhibits growth in vitro and reduces tumorigenicity. Additionally, inducible knockdown of SOX2 in PDAC cells reduces growth in vitro and in vivo. Thus, growth and tumorigenicity of PDAC cells is highly dependent on the expression of optimal levels of SOX2 - a hallmark of molecular rheostats. We also determined that SOX2 alters the responses of PDAC cells to drugs used in PDAC clinical trials. Increasing SOX2 reduces growth inhibition mediated by MEK and AKT inhibitors; whereas knockdown of SOX2 further reduces growth when PDAC cells are treated with these inhibitors. Thus, targeting SOX2, or its mode of action, could improve the treatment of PDAC.

Original languageEnglish (US)
Pages (from-to)34890-34906
Number of pages17
JournalOncotarget
Volume7
Issue number23
DOIs
StatePublished - Jun 7 2016

Fingerprint

Adenocarcinoma
Growth
Pharmaceutical Preparations
Cell Line
Stem Cell Factor
Mitogen-Activated Protein Kinase Kinases
Neoplasms
Transcription Factors
Clinical Trials
In Vitro Techniques

Keywords

  • AKT inhibitors
  • Drug resistance
  • MEK inhibitors
  • Pancreatic cancer
  • SOX2

ASJC Scopus subject areas

  • Oncology

Cite this

SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. / Wuebben, Erin L.; Wilder, Phillip J.; Cox, Jesse L.; Grunkemeyer, James A.; Caffrey, Thomas; Hollingsworth, Michael A; Rizzino, A Angie.

In: Oncotarget, Vol. 7, No. 23, 07.06.2016, p. 34890-34906.

Research output: Contribution to journalArticle

Wuebben, Erin L. ; Wilder, Phillip J. ; Cox, Jesse L. ; Grunkemeyer, James A. ; Caffrey, Thomas ; Hollingsworth, Michael A ; Rizzino, A Angie. / SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells. In: Oncotarget. 2016 ; Vol. 7, No. 23. pp. 34890-34906.
@article{d586e9f2ba6f40b8b88e838ff295b6f1,
title = "SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is a highly deadly malignancy. Expression of the stem cell transcription factor SOX2 increases during progression of PDAC. Knockdown of SOX2 in PDAC cell lines decreases growth in vitro; whereas, stable overexpression of SOX2 in one PDAC cell line reportedly increases growth in vitro. Here, we reexamined the role of SOX2 in PDAC cells, because inducible SOX2 overexpression in other tumor cell types inhibits growth. In this study, four PDAC cell lines were engineered for inducible overexpression of SOX2 or inducible knockdown of SOX2. Remarkably, inducible overexpression of SOX2 in PDAC cells inhibits growth in vitro and reduces tumorigenicity. Additionally, inducible knockdown of SOX2 in PDAC cells reduces growth in vitro and in vivo. Thus, growth and tumorigenicity of PDAC cells is highly dependent on the expression of optimal levels of SOX2 - a hallmark of molecular rheostats. We also determined that SOX2 alters the responses of PDAC cells to drugs used in PDAC clinical trials. Increasing SOX2 reduces growth inhibition mediated by MEK and AKT inhibitors; whereas knockdown of SOX2 further reduces growth when PDAC cells are treated with these inhibitors. Thus, targeting SOX2, or its mode of action, could improve the treatment of PDAC.",
keywords = "AKT inhibitors, Drug resistance, MEK inhibitors, Pancreatic cancer, SOX2",
author = "Wuebben, {Erin L.} and Wilder, {Phillip J.} and Cox, {Jesse L.} and Grunkemeyer, {James A.} and Thomas Caffrey and Hollingsworth, {Michael A} and Rizzino, {A Angie}",
year = "2016",
month = "6",
day = "7",
doi = "10.18632/oncotarget.8994",
language = "English (US)",
volume = "7",
pages = "34890--34906",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells

AU - Wuebben, Erin L.

AU - Wilder, Phillip J.

AU - Cox, Jesse L.

AU - Grunkemeyer, James A.

AU - Caffrey, Thomas

AU - Hollingsworth, Michael A

AU - Rizzino, A Angie

PY - 2016/6/7

Y1 - 2016/6/7

N2 - Pancreatic ductal adenocarcinoma (PDAC) is a highly deadly malignancy. Expression of the stem cell transcription factor SOX2 increases during progression of PDAC. Knockdown of SOX2 in PDAC cell lines decreases growth in vitro; whereas, stable overexpression of SOX2 in one PDAC cell line reportedly increases growth in vitro. Here, we reexamined the role of SOX2 in PDAC cells, because inducible SOX2 overexpression in other tumor cell types inhibits growth. In this study, four PDAC cell lines were engineered for inducible overexpression of SOX2 or inducible knockdown of SOX2. Remarkably, inducible overexpression of SOX2 in PDAC cells inhibits growth in vitro and reduces tumorigenicity. Additionally, inducible knockdown of SOX2 in PDAC cells reduces growth in vitro and in vivo. Thus, growth and tumorigenicity of PDAC cells is highly dependent on the expression of optimal levels of SOX2 - a hallmark of molecular rheostats. We also determined that SOX2 alters the responses of PDAC cells to drugs used in PDAC clinical trials. Increasing SOX2 reduces growth inhibition mediated by MEK and AKT inhibitors; whereas knockdown of SOX2 further reduces growth when PDAC cells are treated with these inhibitors. Thus, targeting SOX2, or its mode of action, could improve the treatment of PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is a highly deadly malignancy. Expression of the stem cell transcription factor SOX2 increases during progression of PDAC. Knockdown of SOX2 in PDAC cell lines decreases growth in vitro; whereas, stable overexpression of SOX2 in one PDAC cell line reportedly increases growth in vitro. Here, we reexamined the role of SOX2 in PDAC cells, because inducible SOX2 overexpression in other tumor cell types inhibits growth. In this study, four PDAC cell lines were engineered for inducible overexpression of SOX2 or inducible knockdown of SOX2. Remarkably, inducible overexpression of SOX2 in PDAC cells inhibits growth in vitro and reduces tumorigenicity. Additionally, inducible knockdown of SOX2 in PDAC cells reduces growth in vitro and in vivo. Thus, growth and tumorigenicity of PDAC cells is highly dependent on the expression of optimal levels of SOX2 - a hallmark of molecular rheostats. We also determined that SOX2 alters the responses of PDAC cells to drugs used in PDAC clinical trials. Increasing SOX2 reduces growth inhibition mediated by MEK and AKT inhibitors; whereas knockdown of SOX2 further reduces growth when PDAC cells are treated with these inhibitors. Thus, targeting SOX2, or its mode of action, could improve the treatment of PDAC.

KW - AKT inhibitors

KW - Drug resistance

KW - MEK inhibitors

KW - Pancreatic cancer

KW - SOX2

UR - http://www.scopus.com/inward/record.url?scp=84973645480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973645480&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8994

DO - 10.18632/oncotarget.8994

M3 - Article

C2 - 27145457

AN - SCOPUS:84973645480

VL - 7

SP - 34890

EP - 34906

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -